Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma, but development was discontinued in 2013. No reason was given but SG plan to start clinical trials of in 2014.
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
CAS number |
|
ChemSpiderID |
|
KEGG |
|
legal status |
|
molecular weight |
|
source |
|
synonyms |
|
target | |
type |
|
UNII |
|
has abstract |
|
Chemical Formula |
|
gold:hypernym | |
chemical formula |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
FDA UNII code |
|
KEGG |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |